CLYM (US) share price forecast & AI signal — Climb Bio, Inc
Week of 2026-10-30 · Healthcare
Exact confidence, 1-week / 1-month / 3-month breakdown, plain-English AI write-up, bull-vs-bear debate, support & resistance.
Get 5 free tokens — no card Already a member? Open the full analysisWhat the model sees in CLYM
Climb Bio, Inc is a Healthcare stock listed on the US. For the week of 2026-10-30 the ACE machine-learning model rates it a SELL with high confidence, based on technical indicators and the stock's own historical patterns across three time horizons. The direction is updated every model run.
About Climb Bio, Inc
Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug which is in phase 2 clinical trials for the treatment of primary membranous nephropathy and immune thrombocytopenia; and Phase 1b clinical trial indicated for the systemic lupus erythematosus. In addition, the company is developing CLYM116, a preclinical stage anti A Proliferation-inducing Ligand (APRIL) monoclonal antibody for the treatment of immunoglobin A...
Recent closes
| Date | Close |
|---|---|
| 2026-11-06 | $10.29 |
| 2026-11-05 | $8.87 |
| 2026-11-04 | $9.33 |
| 2026-11-03 | $9.75 |
| 2026-11-02 | $9.74 |
| 2026-10-30 | $10.25 |
| 2026-10-29 | $10.33 |
CLYM FAQ
Is Climb Bio, Inc (CLYM) a buy or sell this week?
The ACE Stock Bots machine-learning model rates CLYM a SELL for the week of 2026-10-30 with high confidence. The exact confidence and the 1-week, 1-month and 3-month breakdown are free with a signup (5 analysis tokens, no card).
What is the AI share price forecast for CLYM?
Every week the model scores CLYM across three horizons using technical indicators and the stock's own historical patterns. An AI then writes a plain-English summary with support and resistance levels, and a bull analyst and a bear analyst argue the case.
Is this financial advice?
No. ACE Stock Bots provides general information generated by software. It does not consider your objectives, financial situation or needs. Read the disclaimer and consider licensed advice before acting.
Other Healthcare stocks on the US
This week's top US picks · All US stocks
Signals are generated by software for general information only and are not a recommendation to buy or sell. See the disclaimer.